Comparison of ceftiofur hydrochloride and estradiol cypionate for metritis prevention and reproductive performance in dairy cows affected with retained fetal membranes.
The objective of this study was to compare the effect of ceftiofur hydrochloride and estradiol cypionate (ECP) administration for metritis prevention and reproductive performance in dairy cows affected with retained fetal membranes (RFMs). After parturition, 97 dairy cows affected with RFM from a single dairy herd were randomly allocated to 1 of 3 treatment groups. Cows in-group 1 (n=31) were treated daily for 5 days with ceftiofur hydrochloride (2.2mg/kg, i.m.); cows in group 2 (n=33) were treated once with ECP (4 mg, i.m.); and cows in group 3 (n=33) were not treated. The proportion of cows with metritis, uterine involution patterns and the calving-to-conception interval were compared between groups. The proportion of cows that developed metritis was significantly different (P<0.05) in cows treated with ceftiofur hydrochloride (13%), compared with cows treated with ECP (42%) or cows that received no treatment (42%). Uterine involution patterns (i.e. median time to complete retraction of the uterus and mean diameter measure of cervix and uterine horns) were not significantly different between groups. Cows treated with ECP were 0.40 times as likely to conceive as control cows (P=0.05); median time to conception in cows treated with ECP (192 days) was longer, compared to control cows (124 days). We conclude that systemic administration of ceftioufur hydrochloride is beneficial for prevention of metritis, but its effect on reproductive performance was not significantly different to that of ECP or no treatment. In addition, administration of ECP did not have beneficial effects on metritis prevention and reproductive performance.
Risco
C A
CA
Department of Large Animal Clinical Sciences, College of Veterinary Medicine, University of Florida, Gainesville, FL 32610-0136, USA.
Hernandez
J
J
D000818:Animals; D002417:Cattle; D002418:Cattle Diseases / Q000188:drug therapy / Q000503:physiopathology / Q000517:prevention & control*; D002511:Cephalosporins / Q000494:pharmacology / Q000627:therapeutic use*; D003271:Contraceptive Agents, Female / Q000494:pharmacology / Q000627:therapeutic use*; D004716:Endometritis / Q000517:prevention & control / Q000662:veterinary*; D004958:Estradiol / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D007273:Injections, Intramuscular / Q000662:veterinary; D018457:Placenta, Retained / Q000188:drug therapy / Q000503:physiopathology / Q000662:veterinary; D011247:Pregnancy; D011644:Puerperal Disorders / Q000517:prevention & control / Q000662:veterinary; D011897:Random Allocation; D012098:Reproduction / Q000187:drug effects*; D016896:Treatment Outcome
D002511:Cephalosporins; D003271:Contraceptive Agents, Female; D004958:Estradiol; C007630:estradiol 17 beta-cypionate; C053503:ceftiofur